Oxford BioTherapeutics

Executive Summary

Oxford BioTherapeutics (OBT) is a private Swiss biotechnology company headquartered in Basel, dedicated to developing next-generation oncology treatments. Founded in 2008, the company focuses on targeted therapies including Antibody-Drug Conjugates (ADCs), Immuno-oncology, T-Cell Engagers (TCEs), and radiopharmaceuticals. OBT leverages its proprietary platforms to discover and develop novel antibody-based therapeutics aimed at addressing significant unmet needs in cancer. Currently operating at Phase 1 stage, the company has not disclosed specific pipeline programs or financial details, but its diversified approach across multiple therapeutic modalities positions it within the competitive oncology landscape. Despite limited public information, Oxford BioTherapeutics' strategic focus on high-potential modalities such as ADCs and TCEs aligns with industry trends. The company's private status and early-stage pipeline imply higher risk but also potential for upside if clinical data proves promising. Near-term value drivers include potential clinical data readouts from ongoing or planned Phase 1 trials, as well as possible partnership or licensing agreements that could validate its platforms and provide non-dilutive funding. The company's location in Basel, a major biotech hub, may facilitate collaborations.

Upcoming Catalysts (preview)

• H2 2026Initial Phase 1 Clinical Data Readout40% success
• 2026Partnership or Licensing Deal for ADC Platform50% success
• Q3 2026New IND Filing for T-Cell Engager Program30% success